Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 15/20 | 0.55 |
| ▸ | ADCY6 | O43306 | 3/20 | 0.55 |
| ▸ | ADCY3 | O60266 | 3/20 | 0.55 |
| ▸ | ADCY9 | O60503 | 3/20 | 0.55 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.55 |
| ▸ | ADCY8 | P40145 | 3/20 | 0.55 |
| ▸ | ADCY7 | P51828 | 3/20 | 0.55 |
| ▸ | ADCY2 | Q08462 | 3/20 | 0.55 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.55 |
| ▸ | ADCY4 | Q8NFM4 | 3/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765908 | 0.91 | GCGR (0.61) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL1765098 | 0.91 | GCGR (0.67) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL1765806 | 0.88 | GCGR (0.61) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL1765507 | 0.87 | GCGR (0.49) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL1765799 | 0.86 | GCGR (0.54) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL1765734 | 0.85 | GCGR (0.55) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL1765861 | 0.84 | GCGR (0.58) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL1765462 | 0.82 | GCGR (0.56) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL1765785 | 0.82 | GCGR (0.66) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL1765781 | 0.82 | GCGR (0.68) | GCGRADCY6ADCY3ADCY9ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-7816557-B2 | 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2159221-A1 | Glucagon receptor antagonists, preparation and therapeutic uses | Eli Lilly & Company (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124648-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | GCGR 2/4885ADCY6 214/4885ADCY3 208/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GCGR 2/4885ADCY6 214/4885ADCY3 208/4885 |
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | GCGR 2/4885ADCY6 214/4885ADCY3 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.